Updates in arteriovenous malformation management: The post-ARUBA era

James Feghali, Judy Huang

Research output: Contribution to journalReview article

Abstract

Brain arteriovenous malformations (AVMs) are complex and heterogeneous lesions that can rupture, causing significant morbidity and mortality. While ruptured lesions are usually treated, the management of unruptured AVMs remains unclear. A Randomized trial of Unruptured Brain Arteriovenous Malformations (ARUBA) was the first trial conducted to compare the effects of medical and interventional therapy. Although it concluded that medical therapy was superior in preventing stroke and death over a follow-up period of 33 months, the findings were met with intense criticism regarding several aspects of study design, progression, and analysis/conclusion. Namely, the increased use of stand-alone embolisation relative to microsurgery in a cohort with predominantly low-grade lesions combined with a short follow-up period amplified treatment risk. Subsequently, several observational studies were conducted on ARUBA-eligible patients to investigate the safety and efficacy of microsurgery, radiosurgery, and endovascular embolisation over longer follow-up periods. These reports showed that favourable safety profiles and cure rates can be achieved with appropriate patient selection and judicious use of different treatment modalities in multidisciplinary centres. Since large prospective randomised trials on AVMs may not be feasible, it is important to make use of practice-based data beyond the flawed ARUBA study to optimise patients' lifetime outcomes.

Original languageEnglish (US)
JournalStroke and Vascular Neurology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Arteriovenous Malformations
Brain
Microsurgery
Safety
Radiosurgery
Therapeutics
Patient Selection
Observational Studies
Rupture
Stroke
Morbidity
Mortality

Keywords

  • hemorrhage
  • intracranial arteriovenous malformations
  • microsurgery
  • radiosurgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Updates in arteriovenous malformation management : The post-ARUBA era. / Feghali, James; Huang, Judy.

In: Stroke and Vascular Neurology, 01.01.2019.

Research output: Contribution to journalReview article

@article{49389ab891e14348b5773d7683b0e0c4,
title = "Updates in arteriovenous malformation management: The post-ARUBA era",
abstract = "Brain arteriovenous malformations (AVMs) are complex and heterogeneous lesions that can rupture, causing significant morbidity and mortality. While ruptured lesions are usually treated, the management of unruptured AVMs remains unclear. A Randomized trial of Unruptured Brain Arteriovenous Malformations (ARUBA) was the first trial conducted to compare the effects of medical and interventional therapy. Although it concluded that medical therapy was superior in preventing stroke and death over a follow-up period of 33 months, the findings were met with intense criticism regarding several aspects of study design, progression, and analysis/conclusion. Namely, the increased use of stand-alone embolisation relative to microsurgery in a cohort with predominantly low-grade lesions combined with a short follow-up period amplified treatment risk. Subsequently, several observational studies were conducted on ARUBA-eligible patients to investigate the safety and efficacy of microsurgery, radiosurgery, and endovascular embolisation over longer follow-up periods. These reports showed that favourable safety profiles and cure rates can be achieved with appropriate patient selection and judicious use of different treatment modalities in multidisciplinary centres. Since large prospective randomised trials on AVMs may not be feasible, it is important to make use of practice-based data beyond the flawed ARUBA study to optimise patients' lifetime outcomes.",
keywords = "hemorrhage, intracranial arteriovenous malformations, microsurgery, radiosurgery",
author = "James Feghali and Judy Huang",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/svn-2019-000248",
language = "English (US)",
journal = "Stroke and Vascular Neurology",
issn = "2059-8688",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Updates in arteriovenous malformation management

T2 - The post-ARUBA era

AU - Feghali, James

AU - Huang, Judy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Brain arteriovenous malformations (AVMs) are complex and heterogeneous lesions that can rupture, causing significant morbidity and mortality. While ruptured lesions are usually treated, the management of unruptured AVMs remains unclear. A Randomized trial of Unruptured Brain Arteriovenous Malformations (ARUBA) was the first trial conducted to compare the effects of medical and interventional therapy. Although it concluded that medical therapy was superior in preventing stroke and death over a follow-up period of 33 months, the findings were met with intense criticism regarding several aspects of study design, progression, and analysis/conclusion. Namely, the increased use of stand-alone embolisation relative to microsurgery in a cohort with predominantly low-grade lesions combined with a short follow-up period amplified treatment risk. Subsequently, several observational studies were conducted on ARUBA-eligible patients to investigate the safety and efficacy of microsurgery, radiosurgery, and endovascular embolisation over longer follow-up periods. These reports showed that favourable safety profiles and cure rates can be achieved with appropriate patient selection and judicious use of different treatment modalities in multidisciplinary centres. Since large prospective randomised trials on AVMs may not be feasible, it is important to make use of practice-based data beyond the flawed ARUBA study to optimise patients' lifetime outcomes.

AB - Brain arteriovenous malformations (AVMs) are complex and heterogeneous lesions that can rupture, causing significant morbidity and mortality. While ruptured lesions are usually treated, the management of unruptured AVMs remains unclear. A Randomized trial of Unruptured Brain Arteriovenous Malformations (ARUBA) was the first trial conducted to compare the effects of medical and interventional therapy. Although it concluded that medical therapy was superior in preventing stroke and death over a follow-up period of 33 months, the findings were met with intense criticism regarding several aspects of study design, progression, and analysis/conclusion. Namely, the increased use of stand-alone embolisation relative to microsurgery in a cohort with predominantly low-grade lesions combined with a short follow-up period amplified treatment risk. Subsequently, several observational studies were conducted on ARUBA-eligible patients to investigate the safety and efficacy of microsurgery, radiosurgery, and endovascular embolisation over longer follow-up periods. These reports showed that favourable safety profiles and cure rates can be achieved with appropriate patient selection and judicious use of different treatment modalities in multidisciplinary centres. Since large prospective randomised trials on AVMs may not be feasible, it is important to make use of practice-based data beyond the flawed ARUBA study to optimise patients' lifetime outcomes.

KW - hemorrhage

KW - intracranial arteriovenous malformations

KW - microsurgery

KW - radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85072626867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072626867&partnerID=8YFLogxK

U2 - 10.1136/svn-2019-000248

DO - 10.1136/svn-2019-000248

M3 - Review article

AN - SCOPUS:85072626867

JO - Stroke and Vascular Neurology

JF - Stroke and Vascular Neurology

SN - 2059-8688

ER -